PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 16, 2019New England Journal of Medicine3,474 citationsOpen Access

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

View Full Paper
BRBrian I. RiniEPElizabeth R. PlimackVSV.P. Stus

Key Points

  • This study aims to compare the efficacy of pembrolizumab plus axitinib versus sunitinib in patients with advanced renal-cell carcinoma.
  • Randomized trial conducted among previously untreated patients with advanced renal-cell carcinoma.
  • Patients received either pembrolizumab plus axitinib or sunitinib.
  • Clinical outcomes measured included overall survival, progression-free survival, and objective response rate.
  • Pembrolizumab plus axitinib resulted in significantly longer overall survival compared to sunitinib.
  • Progression-free survival was also significantly longer in the pembrolizumab plus axitinib group.
  • The combination treatment yielded a higher objective response rate compared to sunitinib.

Abstract

Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Rini et al. (2019) studied this question.

synapsesocial.com/papers/69d7c01a3b601d7be3ae2aedhttps://doi.org/10.1056/nejmoa1816714
Ask AI
Helpful
Bookmark
Share
View Full Paper